Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

About this update from Contineum Therapeutics, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1875,"height":663,"url":"https://media.zenfs.com/en/business-wire.com/e782d2f08e557e85d00de7c0dc1fe2c1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NYqUoJP9vaolqs5H6ucjkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e782d2f08e557e85d00de7c0dc1fe2c1","width":960,"height":339},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/d5Vu4bpmfcVFE_ydEJ.V2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e782d2f08e557e85d00de7c0dc1fe2c1","width":1200,"height":424}},"lazy":false},{"type":"text","content":"SAN DIEGO, December 11, 2025--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the commencement of an underwritten public offering of $75.0 million of shares of its Class A common stock. In addition, Contineum intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. All securities in the proposed offering are to be sold by Contineum. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.","length":927,"tagName":"p"},{"type":"text","content":"Goldman Sachs & Co. LLC, Leerink Partners, Stifel, RBC Capital Markets and William Blair are acting as joint book-running managers for the proposed offering. Jones is acting as manager for the proposed offering.","length":215,"tagName":"p"},{"type":"text","content":"A registration statement relating to the securities to be sold in the proposed offering was filed with the U.S. Securities and Exchange Commission (SEC) on May 14, 2025 and was declared effective by the SEC on May 23, 2025. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. The proposed offering will be made only by means of a...

More updates from Contineum Therapeutics, Inc.